Dong OM, Herring W, Chopra P, Elpers B, Johannesen K. A targeted literature review of lung function decline in idiopathic pulmonary fibrosis to improve survival predictions in cost-effectiveness analyses. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S148. doi: 10.1016/j.jval.2024.03.2259
Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S. Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S78. doi: 10.1016/j.jval.2023.03.405
Dong O, Purser M, Herring WL, Mladsi DM, Gallagher M, Chawla A, Leiding JW, Andemariam B. Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S115-6. doi: 10.1016/j.jval.2023.03.611
Perugini M, Johnson TJ, Beume TM, Dong OM, Guerino J, Hu H, Kerr K, Kindilien S, Nuijten M, Ofili TU, Taylor M, Wong A, Freijer K. Are we ready for a new approach to comparing coverage and reimbursement policies for medical nutrition in key markets: an ISPOR special interest group report. Value Health. 2022 May;25(5):677-84. doi: 10.1016/j.jval.2022.01.011
Dong OM, Poonnen PJ, Winski D, Reed S, Vashistha V, Bates J, Kelley MJ, Voora D. Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value Health. 2022 Apr;25(4):582-94. doi: 10.1016/j.jval.2021.09.017
Dong OM, Wheeler SB, Cruden G, Lee CR, Voora D, Dusetzina SB, Wiltshire T. Cost-effectiveness of multigene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. Value Health. 2020 Jan 1;23(1):61-73. doi: 10.1016/j.jval.2019.08.002
Dong OM, Lee CR, Wheeler S, Voora D, Dusetzina S, Wiltshire T. A cost-effectiveness analysis of multi-gene pharmacogenetic testing in acute coronary syndrome patients following percutaneous coronary intervention. Presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S6.
Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, Lee CR. CYP2C19 guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and one year outcomes following percutaneous coronary intervention. Presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland. [abstract] Value Health. 2017 Oct 1; 20(9):A405. doi: 10.1016/j.jval.2017.08.041
Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, Lee CR, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May 1; 20(5):A276.